SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Encompass Health Corporation (EHC) trades at a trailing P/E of 18.9, forward P/E of 18.0. Trailing earnings yield is 5.29%, forward earnings yield 5.55%. PEG 0.77 (Peter Lynch undervalued ≤1.0). Graham Number is $64.47.
Criteria proven by this page:
- VALUE (52/100, Partial) — mixed signals — some valuation metrics are favorable while others are stretched.
- Forward P/E 18.0 (down from trailing 18.9) — analysts expect earnings to grow, which would improve the valuation.
- PEG Ratio 0.77 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
- Trailing Earnings Yield 5.29% — exceeds typical bond yields (~4.3%), making equity attractive vs fixed income. Forward yield improves to 5.55% as earnings recover.
- Analyst consensus target $153.00 (+43.4% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 70/100 with 3/7 criteria passed.
SharesGrow 7-Criteria Score
~
VALUE
52/100
Price-to-Earnings & upside
Proven by this page
~
HEALTH
67/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — EHC
Valuation Multiples
P/E (TTM)18.9
Forward P/E18.0
PEG Ratio0.77
Forward PEG2.73
P/B Ratio4.39
P/S Ratio1.81
EV/EBITDA9.5
Per Share Data
EPS (TTM)$5.65
Forward EPS (Est.)$5.92
Book Value / Share$32.69
Revenue / Share$59.23
FCF / Share$4.38
Yields & Fair Value
Earnings Yield5.29%
Forward Earnings Yield5.55%
Dividend Yield0.69%
Graham Number$64.47
SharesGrow IV$88.55 (-17%)
Analyst Target$153.00 (+43.4%)
Historical Valuation
| Year |
P/E (TTM) |
PEG Ratio |
P/B Ratio |
P/S Ratio |
Dividend Yield |
| 2016 |
11.8 |
0.32 |
3.97 |
0.80 |
2.87% |
| 2017 |
13.6 |
-9.40 |
3.12 |
0.94 |
2.49% |
| 2018 |
16.4 |
1.73 |
3.61 |
1.12 |
2.10% |
| 2019 |
15.0 |
0.68 |
3.99 |
1.17 |
2.01% |
| 2020 |
22.8 |
-1.07 |
4.08 |
1.82 |
1.73% |
| 2021 |
12.5 |
0.28 |
2.69 |
1.28 |
2.18% |
| 2022 |
21.9 |
-0.64 |
4.53 |
1.36 |
1.67% |
| 2023 |
18.9 |
0.63 |
4.03 |
1.38 |
0.91% |
| 2024 |
20.2 |
0.72 |
4.46 |
1.72 |
0.68% |
| 2025 |
18.8 |
0.78 |
4.37 |
1.80 |
0.67% |
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$2.59 |
$3.65B |
$247.6M |
6.8% |
| 2017 |
$2.69 |
$3.92B |
$256.3M |
6.5% |
| 2018 |
$2.93 |
$4.28B |
$292.3M |
6.8% |
| 2019 |
$3.61 |
$4.61B |
$358.7M |
7.8% |
| 2020 |
$2.85 |
$4.64B |
$284.2M |
6.1% |
| 2021 |
$4.11 |
$5.12B |
$412.2M |
8% |
| 2022 |
$2.70 |
$4.35B |
$271M |
6.2% |
| 2023 |
$3.47 |
$4.8B |
$352M |
7.3% |
| 2024 |
$4.46 |
$5.37B |
$455.7M |
8.5% |
| 2025 |
$5.55 |
$5.94B |
$566.2M |
9.5% |
Analyst Estimates
| Year |
EPS (Avg) |
EPS Range |
Revenue (Avg) |
Revenue Range |
Analysts |
| 2026 |
$5.92 |
$5.52 – $6.05 |
$6.42B |
$6.4B – $6.43B |
8 |
| 2027 |
$6.47 |
$6.05 – $6.65 |
$6.94B |
$6.89B – $7B |
8 |
| 2028 |
$7.04 |
$6.95 – $7.12 |
$7.45B |
$7.45B – $7.45B |
2 |
| 2029 |
$7.69 |
$7.65 – $7.76 |
$7.94B |
$7.9B – $7.99B |
1 |
